Overview

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms

Status:
RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and \<18 years, ≥6 kg body weight \[BW\]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.

Phase:

PHASE2

Details

Lead Sponsor:

Miltenyi Biomedicine GmbH

Collaborator:

PPD, Part of Thermo Fisher Scientific